Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism

Bio2RDF identifier

NCT00291330

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00291330

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00291330

acronym [clinicaltrials_vocabulary:acronym]

RE-COVER I

http://www.w3.org/2001/XMLSchema#string

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

2,564

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this tri ...... of dabigatran over warfarin.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Efficacy and Safety of Dabigat ...... tomatic Venous Thromboembolism

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00291330 [clinicaltrials_resource:5194f0ca1b5f46e6b69f11a054a95a72]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:7978551b5f9c7f4de333b94da2290846]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:3dc27dc2f3a56726f6ab44f209f3aac1]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:4c274ee8c54458f15c989361c90261a1]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:53f5adbf3a31f0178fb6e1ab0dd0bd39]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:d3fed8d0b43cc58cbfcf2672ebe3f1e6]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:d75ec99eeae1630e620c07a56964a7bb]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:de24849556070b19e44b4d0315db17bc]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:e65ca0ccc56cb9b0f23ad8d10171bf25]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180) [clinicaltrials_resource:f181c855f6dbf59eed196d68a4342629]

condition [clinicaltrials_vocabulary:condition]

Thromboembolism [clinicaltrials_resource:8aef77b5a8ef234005539d20511c413f]

condition browse [clinicaltrials_vocabulary:condition-browse]

Venous Thrombosis [clinicaltrials_resource:17ac49d0061cfa6810b1bb4d572eb1d3]

Thromboembolism [clinicaltrials_resource:8aef77b5a8ef234005539d20511c413f]

Venous Thromboembolism [clinicaltrials_resource:9344765d198c205c1f3ff856b11c22c7]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Venous Thrombosis [clinicaltrials_resource:17ac49d0061cfa6810b1bb4d572eb1d3]

Thromboembolism [clinicaltrials_resource:8aef77b5a8ef234005539d20511c413f]

Venous Thromboembolism [clinicaltrials_resource:9344765d198c205c1f3ff856b11c22c7]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00291330 [clinicaltrials_resource:2df1fdaf31cc3028d0830992d75d10be]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2010-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

warfarin (INR 2-3) [clinicaltrials_resource:081ec5d91c89f59795da3d96636820ff]

dabigatran etexilate 150 mg [clinicaltrials_resource:c9c000067f43164e6ea900c84837ce47]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Warfarin [clinicaltrials_resource:00fb95037ac6b3e040933a49bc5cbdfa]

Dabigatran [clinicaltrials_resource:18ceb26a7874adfc4bf05183112c667c]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

link [clinicaltrials_vocabulary:link]

[clinicaltrials_resource:6c5a06eb786486c406ecf9defc088be9]

[clinicaltrials_resource:b234e411309aef08c2aab36c5f29f396]

location [clinicaltrials_vocabulary:location]

1160.53.01035 Boehringer Ingelheim Investigational Site [clinicaltrials_resource:1ee39366c1aa136754499c3f5938d06c]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00291330

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

2

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase III, Randomised, Doubl ...... Approved for This Indication.

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

1.160530029296875e+3

http://www.w3.org/2001/XMLSchema#float

outcome [clinicaltrials_vocabulary:outcome]

Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE [clinicaltrials_resource:NCT00291330/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Boehringer Ingelheim [clinicaltrials_resource:1f5af28df428803ccefd08f103ea82a2]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Argentina: A.N.M.A.T. (National Administration of Medications, Food and Medical Technology) [clinicaltrials_resource:521904ec144d14186863712f14706e13]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00291330 [clinicaltrials_resource:d49c194c02327a617b4ec462bb5a0419]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00291330 [clinicaltrials_resource:c39eefa9c3f9880584be22042c2064e4]

responsible party [clinicaltrials_vocabulary:responsible-party]

Boehringer Ingelheim, Study Chair, Boehringer Ingelheim [clinicaltrials_resource:647bb26ee689091d3c2c5b3dc0e985bd]

secondary id [clinicaltrials_vocabulary:secondary-id]

2005-001999-12

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

start date [clinicaltrials_vocabulary:start-date]

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00291330 study design [clinicaltrials_resource:f296505c1b89a38091bb6875a0d1cc4c]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00291330

verification date [clinicaltrials_vocabulary:verification-date]

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00291330

http://www.w3.org/2001/XMLSchema#string